BioSpace News Archive

Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by Lynx1 Capital Management with participation from existing investors RA Capital Management.

Dr. Andrea Remuzzi and his research team at The University of Bergamo have recently published a randomized-controlled MRI-based computational fluid dynamic study in the Journal of Vascular Access that revealed the impact of VasQ™ External Support on fistula morphology and flow.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx,”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th International Biodetection Technologies Conference.

Domain Therapeutics, today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017.

Rezolut, LLC, a high-growth medical imaging business, is pleased to announce it has entered into a partnership agreement with Centrelake, headquartered in Ontario, CA.

Rapid Medical, a leading developer of advanced neurovascular devices, announces the expansion of its portfolio in the United States and the first Numen™ coil embolization procedure.

Ventilators market research report acts as a valued source of information with which businesses can achieve a telescopic view of the current market trends, consumer’s demands and preferences, market situations, opportunities and market status.

According to Vision Research Reports, the global external urine management products market was surpassed at USD 544.8 million in 2021 and is expected to hit around USD 844.5 million by 2030, growing at a CAGR of 4.99% from 2022 to 2030.

Bayer’s KERENDIA® (finerenone) was recognized by the American Diabetes Association (ADA) Standards of Medical Care in Diabetes—2022 with a new grade A recommendation* for improving cardiovascular (CV) outcomes and reducing the risk of chronic kidney disease (CKD) progression in patients with CKD associated with type 2 diabetes (T2D).

Adial Pharmaceuticals, Inc., issued the following letter to its shareholders from the Company’s CEO, William Stilley.